1-8 of 8 Resource Library
Immuno-oncology is at the forefront of cancer research and is a leader in the global drug development pipeline. This therapeutic strategy enables the body to prevent, control, and eliminate cancer by providing the immune system with tools to discover tumors and strengthen its ability to attack cancer cells.
We understand the importance of furthering Immuno-Oncology research and developed an extensive reagent portfolio encompassing Innate Immunity (Toll-Like Receptors, STING Axis, Inflammasomes), Natural Killers, Adaptive Immunity (T-cells and CAR-T Therapies, B-cells), Immune Checkpoints, Immunosuppression, and other immune pathways. Learn more about our Immuno-oncology assays and targets in this flyer.
1-1 of 1 Products & Services
The AlphaLISA® human CD28/CD86 binding kit is designed for the detection of binding activity between human CD28 and CD86, using a fast and simple homogeneous AlphaLISA assay (no wash steps). This assay can be used to screen for small molecules that inhibit binding, as a competitive ligand binding (CLB) assay to screen therapeutic blocking antibodies, and for potency assays.